McMaster University spinout Fusion Pharmaceuticals has filed for a $100m IPO in the US, putting shareholders such as Facit in line for exits.
Fusion Pharmaceuticals, a Canada-based cancer radiopharmaceuticals developer spun out of McMaster University, has filed for a $100m initial public offering on the Nasdaq Global Market.
The company has not yet settled on a price range or determined the number of shares it will issue.
Founded in 2014, Fusion Pharmaceuticals is developing targeted alpha therapeutics, a type of cancer treatment that relies on equipping molecules, such as antibodies, with radioactive particles – called alpha emitting medical isotopes –…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
